{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:23:23Z","timestamp":1780471403463,"version":"3.54.1"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Elion Therapeutics"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Fusariosis has high mortality rates with limited treatment options. Owing to its rarity, comparative clinical trials are hard to perform. SF001 is a novel, next-generation polyene drug, rationally designed to reduce potential for systemic toxicity, with long-acting, potent, broad-spectrum fungicidal activity. We compared the\n              <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n              activity and\n              <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n              efficacy of SF001 with liposomal amphotericin B (LAMB) in treating immunosuppressed mice infected with hematogenously disseminated fusariosis. The minimum inhibitory concentration (MIC) of SF001 and LAMB against\n              <jats:italic toggle=\"yes\">Fusarium solani<\/jats:italic>\n              or\n              <jats:italic toggle=\"yes\">Fusarium oxysporum<\/jats:italic>\n              strains (at 100% inhibition) ranged between 0.5\u20138 \u00b5g\/mL and 1\u2013&gt;16 \u00b5g\/mL, respectively. In the hematogenously disseminated fusariosis model, treatment with SF001 or LAMB enhanced the median survival time vs placebo (7, 10, and 9 days at 3, 7.5, and 30 mg\/kg of SF001, respectively, and 12.5 days for LAMB at 7.5 mg\/kg vs 6.5 days for placebo,\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt; 0.0001). SF001 and LAMB treatment enhanced the overall survival by day 21 (40% and 25% for SF001 at 7.5 mg\/kg and 30 mg\/kg, respectively, 30% for LAMB at 7.5 mg\/kg and 0% for placebo). The survival data were mirrored in the kidney and brain fungal burden results with ~2\u20133 log\n              <jats:sub>10<\/jats:sub>\n              reduction in conidial equivalents\/gram for either treatment vs placebo. Furthermore, the reduction in tissue fungal burden was corroborated by histopathological data from target organs, showing reduced or no abscesses in SF001- or LAMB-treated mice. Our data show comparable activity of SF001 to LAMB, thereby supporting the continued development of SF001 for the treatment of invasive fusariosis.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01802-24","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T19:44:37Z","timestamp":1743536677000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis"],"prefix":"10.1128","volume":"69","author":[{"given":"Teclegiorgis","family":"Gebremariam","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyou","family":"Gu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoja","family":"Patterson","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio","place":["San Antonio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Youssef","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondus","family":"Alkhazraji","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":true,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio","place":["San Antonio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":true,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center","place":["Torrance, USA"]},{"name":"David Geffen School of Medicine at UCLA","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4557-4801-3.00270-8"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof7100815"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780195148091.003.0016"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00014-07"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0013-2020"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00159-22"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1247491"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2021.12.003"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2023.02.004"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12872"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/429331"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/374557"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.3.1100-1102.2002"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.999"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06710-4"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01631-23"},{"key":"e_1_3_5_18_2","volume-title":"Presented at the 11th Advances Against Aspergillosis and Mucormycosis Conference","author":"Gebremariam T","year":"2024","unstructured":"Gebremariam T, Gu Y, Youssef E, Alkhazraji S, Quran J, Wiederhold NP, Ibrahim AS. 2024. Efficacy assessment of SF001, A 3rd generation polyene antifungal, in the neutropenic mouse model of invasive pulmonary aspergillosis and mucormycosis. Presented at the 11th Advances Against Aspergillosis and Mucormycosis Conference. Milano, Italy."},{"key":"e_1_3_5_19_2","unstructured":"Institute. CLS. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi M38-A2. Wayne PA USA CLSI"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl378"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01735-19"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00380-22"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid3002.231221"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00313-13"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00178-20"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.721-727.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01802-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01802-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:01:15Z","timestamp":1746622875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01802-24"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,7]]}},"alternative-id":["10.1128\/aac.01802-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01802-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"2024-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01802-24"}}